Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore 138648; email:
Institute of Infection and Global Health, University of Liverpool, Liverpool L69 3BX, United Kingdom.
Annu Rev Virol. 2017 Sep 29;4(1):413-427. doi: 10.1146/annurev-virology-101416-041808. Epub 2017 Jun 21.
Chikungunya virus (CHIKV) is an arthropod-borne alphavirus that causes acute and chronic arthritis. The virus reemerged in the Indian Ocean islands in 2005-2006 and is responsible for outbreaks in the Caribbean islands and the Americas since late 2013. Despite the wealth of research over the past 10 years, there are no commercially available antiviral drugs or vaccines. Treatment usually involves analgesics, anti-inflammatory drugs, and supportive care. Most studies have been focused on understanding the pathogenesis of CHIKV infection through clinical observation and with animal models. In this review, the clinical manifestations of CHIKV that define the disease and the use of relevant animal models, from mice to nonhuman primates, are discussed. Understanding key cellular factors in CHIKV infection and the interplay with the immune system will aid in the development of preventive and therapeutic approaches to combat this painful viral disease in humans.
基孔肯雅热病毒(CHIKV)是一种虫媒黄病毒,可引起急性和慢性关节炎。该病毒于 2005-2006 年在印度洋岛屿重新出现,并导致 2013 年底以来加勒比岛屿和美洲的暴发。尽管过去 10 年进行了大量研究,但尚无市售的抗病毒药物或疫苗。治疗通常涉及镇痛药、抗炎药和支持性护理。大多数研究都集中在通过临床观察和动物模型来了解 CHIKV 感染的发病机制。在这篇综述中,讨论了定义该疾病的 CHIKV 的临床表现以及相关动物模型(从小鼠到非人灵长类动物)的应用。了解 CHIKV 感染中的关键细胞因子及其与免疫系统的相互作用将有助于开发预防和治疗方法,以对抗这种在人类中引起疼痛的病毒性疾病。